58115-29-0

Basic information

• Product Name: 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-
• CAS NO: 58115-29-0
• Molecular Formula: C16H12O6
• Molecular Weight: 300.268
• Mol File: 58115-29-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-(58115-29-0)
• EPA Substance Registry System: 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-(58115-29-0)

Safety Data

• Hazardous Substances Data: 58115-29-0(Hazardous Substances Data)

Upstream product

• 90363-40-9 2-(3,4-dihydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one 
• 1201808-03-8 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-methoxy-4H-chromen-4-one 

Downstream Products

• 62346-14-9 7,4′-dihydroxy-5,3′-dimethoxyflavone 
• 72629-61-9 Luteolin-5,4'-dimethylether 
• 491-70-3 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-on 
• 520-34-3 diosmetin 
• 20243-59-8 7-methylluteoline 
• 90363-40-9 2-(3,4-dihydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one 

Relevant articles and documents

Discovery and synthesis of novel luteolin derivatives as DAT agonists

Luteolin, 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one, has been proposed and proved to be a novel dopamine transporter (DAT) activator. In order to develop this potential of luteolin, a series of novel luteolin derivatives were designed, synthesized, and evaluated for their DAT agonistic activities, utilizing constructed Chinese hamster ovary (CHO) cell lines stably expressing rat DAT. Biological screening results demonstrated that luteolin derivatives 1d, 1e, and 4c carry great DAT agonistic potency (EC50 = 0.046, 0.869, and 1.375 μM, respectively) compared with luteolin 8 (EC50 = 1.45 ± 0.29 μM). Luteolin derivative 1d, notably, exhibited a 32-fold-higher DAT agonistic potency than luteolin. These luteolin derivatives represent a novel DAT agonist class, from which lead compounds useful for exploration of additional novel DAT agonists could be drawn.